CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD44

(19)

(11)

EP 1 667 716 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	28.03.2012 Bulletin 2012/13

(45)	Mention of the grant of the patent:
	28.12.2011 Bulletin 2011/52

(21)	Application number: 04761710.5

(22)	Date of filing: 20.08.2004

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
C12Q 1/04^(2006.01)
G01N 33/574^(2006.01)
C07K 16/28^(2006.01)

A61K 47/48^(2006.01)
G01N 33/569^(2006.01)
A61P 35/00^(2006.01)

(86)	International application number:
	PCT/CA2004/001546

(87)	International publication number:
	WO 2005/018667 (03.03.2005 Gazette 2005/09)

(54)	CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD44 ZYTOTOXIZITÄTSMEDIATION IN ZELLEN DIE AUF EINE OBERFLÄCHENEXPRESSION VON CD44 HINWEISEN MISE EN EVIDENCE D'UNE EXPRESSION SURFACIELLE DU CD44 PAR LA CYTOTOXICITE DE CELLULES

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

22.08.2003 US 647818

(43)	Date of publication of application:
	14.06.2006 Bulletin 2006/24

(73)	Proprietor: F. Hoffmann-La Roche AG
	4070 Basel (CH)

(72)	Inventors:
	YOUNG, David S. F. Toronto, Ontario M5J 2S7 (CA) HAHN, Susan, E. Toronto, Ontario M6P 3N7 (CA) FINDLAY, Helen, P. Toronto, Ontario M6P 3E9 (CA)

(74)	Representative: Vossius & Partner
	Siebertstrasse 4 81675 München 81675 München (DE)

(56)

References cited: :

WO-A-03/055515
US-A1- 2002 041 877
US-B1- 6 180 357

US-A- 5 616 468
US-A1- 2004 001 789

D. NAOR ET AL.: "CD44: Structure, function and association with the malignant process." ADVANCES IN CANCER RESEARCH, vol. 71, 1997, pages 241-319, XP000952636 U.S.A.
R. OOSTENDORP ET AL.: "Evidence for differences in the mechanisms by which antibodies against CD44 promote adhesion of erythroid and granulopoietic progenitors to marrow stromal cells." BRITISH JOURNAL OF HAEMATOLOGY, vol. 101, 1998, pages 436-445, XP002427339

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).